FDC (NSE:FDC, BOM:531599) has received abbreviated new drug application approval from the U.S, Food and Drug Administration for Cefixime for Oral Suspension, according to a Monday filing with the Indian stock exchanges.
Cefixime is used to treat various bacterial infections.
The approval has been given for the strengths of 100 mg/5 mL and 200 mg/5 mL of the drug.
The company's shares were down nearly 2% in recent trade.